Tagged with DIA

India Suresh Pattathil wears two hats within India’s vast pharma ecosystem. Not only is he responsible for managing AbbVie India as its Managing Director and GM, he also advocates for broader pharma interests as president of the Organization of Pharmaceutical Producers of India (OPPI). He speaks about India’s goal of fostering…

India In the latest blow to Indian pharma’s reputation, the European Medicines Agency (EMA) has recommended the suspension of marketing authorisations for a large number of generics tested by Indian CRO Synapse Labs. While the Indian government has taken steps to regulate the industry and improve quality, including a new Drugs,…

India Director of the oldest and largest cancer centre in India, the Tata Memorial Hospital, C S Pramesh also heads up the National Cancer Grid (NCG), a nationwide network of over 300 cancer centres and research institutions. He outlines the pioneering research-based work of the Tata Memorial Hospital and explains the…

India Over the course of his 40-year career, oncologist Dr Ramakant Deshpande has taken an active role in the evolution of cancer care in India and in 2017 he became the executive chairman of the Asian Cancer Institute, a cancer care centre aimed at delivering quality care while addressing affordability. He…

USA The US Food and Drug Administration has increasingly recognized the importance of diversity and representation in clinical trials over the past few decades. This evolution reflects growing awareness across medicine that differences in age, gender, race, and ethnicity can impact disease risk, treatment response, and health outcomes. Darshan Kulkarni of…

Global AI is the buzzword du jour across all industries, but what is needed for it to truly make a difference in clinical trials? Writing in December 2023’s DIA Global Forum magazine, Lokavant’s Rohit Nambisan lays out the three essential characteristics for AI impact in clinical research, foregrounding the vital importance…

India Ayushman Bharat, launched in 2018, is a monumental scheme addressing the lack of healthcare accessibility and affordability for over 500 million people in India. Dr Indu Bhushan, Ayushman Bharat’s inaugural CEO, explains how the scheme was swiftly implemented, utilizing socio-economic caste census data to determine eligibility inclusively; how it reduces…

India India’s chemical industry is of vital importance to several industries, including pharmaceuticals, and exported USD 30.18 billion worth of products in 2022-23. Chemexcil’s Raghuveer Kini discusses his industry’s key role in global supply chains, his association’s strategic goals and achievements, and the need for continued international collaboration.   In essence,…

India Pratima Reddy, GM at Merck Healthcare India reviews the importance of Merck’s Indian affiliate, discusses the recent reforms that have contributed both to improving patient access and to fostering foreign investments and innovation, and explains the representation of Merck’s portfolio in the country, and how the company navigates the local…

USA Eli Lilly has turned its numbers around and become the world’s most valuable pharma company, thanks to its type 2 diabetes and off-label use obesity drug tirzeptide, which generated no less than USD 1.4 billion in its first full quarter on the market. As the US firm prepares to launch…

India The Indian pharma industry has demonstrated spectacular growth based on its strength as a global generics manufacturer. Yet Indian pharma is not merely resting on its laurels. After shining through the COVID-19 pandemic and despite recent quality issues, the country’s pharmaceutical sector is looking to refocus its efforts on innovation…

India Sandeep Verma shares his journey of establishing Bayer’s consumer healthcare division in India and reflects on the challenges faced during the division’s inception amidst the COVID-19 pandemic, emphasizing the importance of trust in collaborations with manufacturing units. He delves into Bayer’s strategies for market expansion, dispelling myths about self-care in…